Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of CKD-348 vs Co-administration of Components in Healthy Volunteers
NCT04304547Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-348 in hypertension (HTN) and dyslipidemia (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the last measurable concentration. Started Feb 2020; status: completed.
02
Drugs
CKD-348
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04304547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04304547.